Windlas Biotech Q4 FY26 Results: PAT Rs 16 Cr

Windlas Biotech Q4 FY26 results were declared on May 21, 2026. The company reported PAT of Rs 16 crore for the quarter ended March 31, 2026, down 0.0% YoY compared to Rs 16 crore in Q4 FY25. Revenue from operations stood at Rs 238 crore, up 17.0% YoY. Results are on a Standalone basis. Windlas Biotech is a Pharma CDMO company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Windlas Biotech Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	238	203	+17.0%
Gross Profit	Rs 17 crore	17	+0.0%
Net Profit	16	16	+0.0%
Basis	Standalone

Note: Windlas Biotech Q4 FY26 results declared May 21, 2026. Verify from BSE/NSE audited filings before investment decisions.

Windlas Biotech Q4 FY26 Performance Analysis

The Windlas Biotech Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter. The company delivered steady performance in line with sector trends. Windlas Biotech operates in the Pharma CDMO sector, which benefited from India’s GDP growth above 6.5% in FY26.

Revenue grew 17% YoY to Rs 238 crore, driven by strong demand and business expansion.

Screen the best stocks on the Univest Screener.

Key Factors Driving Windlas Biotech Q4 FY26 Results

Revenue and Business Performance

Windlas Biotech Q4 FY26 revenue of Rs 238 crore was up 17.0% YoY. Revenue momentum reflects steady demand in the Pharma CDMO business.

Profitability and Margins

the business PAT of Rs 16 crore down 0.0% YoY. Sustaining profitability while scaling revenues remains the key management priority.

India Macro Backdrop

The January to March 2026 quarter benefited from India’s GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore for FY27, and resilient domestic consumption. RBI’s accommodative stance supported credit and demand conditions. The Pharma CDMO sector saw strong tailwinds during this period.

FY27 Outlook

Following the firm results, management commentary on FY27 revenue guidance, margin expansion roadmap, and capital allocation will be key investor watchpoints. The Pharma CDMO sector continues to benefit from India’s long-term structural growth.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Also Read

• LIC Q4 FY26 Results: PAT Rs 23,420 Crore
• JSW Cement Q4 FY26 Results: PAT Rs 356 Crore
• Prestige Estates Q4 FY26 Results: PAT Rs 327 Crore
• Univest Blogs: Latest Stock Market Research and Analysis

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.